Helen I. Torley's most recent trade in Halozyme Therapeutics Inc. was a trade of 92,714 Performance Stock Units done . Disclosure was reported to the exchange on Feb. 9, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2026 | 92,714 | 92,714 | - | - | Performance Stock Units | |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2026 | 53,847 | 53,847 | - | - | Option to Purchase Common Stock | |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2026 | 50,013 | 50,013 | - | - | Restricted Stock Units | |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2026 | 24,985 | 144,400 | - | - | Performance Stock Units | |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2026 | 19,807 | 51,171 | - | - | Performance Stock Units | |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Feb 2026 | 20,000 | 231,923 | - | - | Option to Purchase Common Stock | |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Feb 2026 | 20,000 | 211,923 | - | - | Option to Purchase Common Stock | |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.07 per share. | 03 Feb 2026 | 20,000 | 728,719 (0%) | 0% | 12.1 | 241,400 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.07 per share. | 03 Feb 2026 | 20,000 | 728,719 (0%) | 0% | 12.1 | 241,400 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 77.54 per share. | 03 Feb 2026 | 10,100 | 708,719 (0%) | 0% | 77.5 | 783,154 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Feb 2026 | 10,000 | 201,923 | - | - | Option to Purchase Common Stock | |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.07 per share. | 03 Feb 2026 | 10,000 | 718,719 (0%) | 0% | 12.1 | 120,700 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 76.94 per share. | 03 Feb 2026 | 9,900 | 718,819 (0%) | 0% | 76.9 | 761,666 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 75.94 per share. | 03 Feb 2026 | 9,659 | 716,509 (0%) | 0% | 75.9 | 733,543 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 76.73 per share. | 03 Feb 2026 | 7,790 | 708,719 (0%) | 0% | 76.7 | 597,758 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 78.38 per share. | 03 Feb 2026 | 5,376 | 713,343 (0%) | 0% | 78.4 | 421,366 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 78.94 per share. | 03 Feb 2026 | 4,624 | 708,719 (0%) | 0% | 78.9 | 365,000 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 74.88 per share. | 03 Feb 2026 | 2,551 | 726,168 (0%) | 0% | 74.9 | 191,016 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Dec 2025 | 165,522 | 165,522 | - | - | Performance Stock Units | |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 26 Nov 2025 | 25,000 | 708,719 (0%) | 0% | 0 | Common Stock | |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Nov 2025 | 16,569 | 0 | - | - | Option to Purchase Common Stock | |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.11 per share. | 26 Nov 2025 | 16,569 | 725,288 (0%) | 0% | 8.1 | 134,375 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 68.51 per share. | 26 Nov 2025 | 10,406 | 714,882 (0%) | 0% | 68.5 | 712,936 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 69.44 per share. | 26 Nov 2025 | 5,402 | 709,480 (0%) | 0% | 69.4 | 375,120 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 70.36 per share. | 26 Nov 2025 | 500 | 708,980 (0%) | 0% | 70.4 | 35,181 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 71.60 per share. | 26 Nov 2025 | 261 | 708,719 (0%) | 0% | 71.6 | 18,688 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.11 per share. | 10 Nov 2025 | 20,000 | 753,719 (0%) | 0% | 8.1 | 162,200 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Nov 2025 | 20,000 | 16,569 | - | - | Option to Purchase Common Stock | |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Nov 2025 | 20,000 | 36,569 | - | - | Option to Purchase Common Stock | |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Nov 2025 | 20,000 | 56,569 | - | - | Option to Purchase Common Stock | |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.11 per share. | 10 Nov 2025 | 20,000 | 753,719 (0%) | 0% | 8.1 | 162,200 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.11 per share. | 10 Nov 2025 | 20,000 | 753,719 (0%) | 0% | 8.1 | 162,200 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 68.71 per share. | 10 Nov 2025 | 19,900 | 733,819 (0%) | 0% | 68.7 | 1,367,409 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 70.22 per share. | 10 Nov 2025 | 12,718 | 741,001 (0%) | 0% | 70.2 | 893,033 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 69.73 per share. | 10 Nov 2025 | 11,500 | 733,719 (0%) | 0% | 69.7 | 801,907 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 71.09 per share. | 10 Nov 2025 | 6,784 | 734,217 (0%) | 0% | 71.1 | 482,268 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 67.89 per share. | 10 Nov 2025 | 4,500 | 749,219 (0%) | 0% | 67.9 | 305,514 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 68.80 per share. | 10 Nov 2025 | 4,000 | 745,219 (0%) | 0% | 68.8 | 275,180 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 71.67 per share. | 10 Nov 2025 | 498 | 733,719 (0%) | 0% | 71.7 | 35,690 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 69.30 per share. | 10 Nov 2025 | 100 | 733,719 (0%) | 0% | 69.3 | 6,930 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.11 per share. | 01 Oct 2025 | 20,000 | 753,719 (0%) | 0% | 8.1 | 162,200 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Oct 2025 | 20,000 | 76,569 | - | - | Option to Purchase Common Stock | |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Oct 2025 | 20,000 | 96,569 | - | - | Option to Purchase Common Stock | |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Oct 2025 | 20,000 | 116,569 | - | - | Option to Purchase Common Stock | |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.11 per share. | 01 Oct 2025 | 20,000 | 753,719 (0%) | 0% | 8.1 | 162,200 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.11 per share. | 01 Oct 2025 | 20,000 | 753,719 (0%) | 0% | 8.1 | 162,200 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 68.47 per share. | 01 Oct 2025 | 14,235 | 739,484 (0%) | 0% | 68.5 | 974,699 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 75.11 per share. | 01 Oct 2025 | 11,705 | 742,014 (0%) | 0% | 75.1 | 879,151 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 71.28 per share. | 01 Oct 2025 | 10,200 | 736,919 (0%) | 0% | 71.3 | 727,036 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 75.69 per share. | 01 Oct 2025 | 8,295 | 733,719 (0%) | 0% | 75.7 | 627,873 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 70.51 per share. | 01 Oct 2025 | 6,600 | 747,119 (0%) | 0% | 70.5 | 465,359 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 70.58 per share. | 01 Oct 2025 | 2,707 | 734,443 (0%) | 0% | 70.6 | 191,065 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 72.06 per share. | 01 Oct 2025 | 2,400 | 734,519 (0%) | 0% | 72.1 | 172,956 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 69.83 per share. | 01 Oct 2025 | 2,334 | 737,150 (0%) | 0% | 69.8 | 162,983 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 71.67 per share. | 01 Oct 2025 | 724 | 733,719 (0%) | 0% | 71.7 | 51,891 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 73.24 per share. | 01 Oct 2025 | 700 | 733,819 (0%) | 0% | 73.2 | 51,265 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 74.67 per share. | 01 Oct 2025 | 100 | 733,719 (0%) | 0% | 74.7 | 7,467 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.11 per share. | 02 Sep 2025 | 20,000 | 753,719 (0%) | 0% | 8.1 | 162,200 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Sep 2025 | 20,000 | 156,569 | - | - | Option to Purchase Common Stock | |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Sep 2025 | 20,000 | 136,569 | - | - | Option to Purchase Common Stock | |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Sep 2025 | 20,000 | 176,569 | - | - | Option to Purchase Common Stock | |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.11 per share. | 02 Sep 2025 | 20,000 | 753,719 (0%) | 0% | 8.1 | 162,200 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.11 per share. | 02 Sep 2025 | 20,000 | 753,719 (0%) | 0% | 8.1 | 162,200 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 73.70 per share. | 02 Sep 2025 | 16,288 | 737,131 (0%) | 0% | 73.7 | 1,200,393 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 74.63 per share. | 02 Sep 2025 | 10,500 | 733,719 (0%) | 0% | 74.6 | 783,636 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 73.54 per share. | 02 Sep 2025 | 9,900 | 743,819 (0%) | 0% | 73.5 | 728,006 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 74.22 per share. | 02 Sep 2025 | 9,500 | 744,219 (0%) | 0% | 74.2 | 705,090 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 74.33 per share. | 02 Sep 2025 | 7,800 | 736,019 (0%) | 0% | 74.3 | 579,751 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 74.15 per share. | 02 Sep 2025 | 3,412 | 733,719 (0%) | 0% | 74.1 | 252,990 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 75.22 per share. | 02 Sep 2025 | 2,300 | 733,719 (0%) | 0% | 75.2 | 173,015 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 72.49 per share. | 02 Sep 2025 | 300 | 753,419 (0%) | 0% | 72.5 | 21,746 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.11 per share. | 11 Aug 2025 | 20,000 | 753,719 (0%) | 0% | 8.1 | 162,200 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Aug 2025 | 20,000 | 196,569 | - | - | Option to Purchase Common Stock | |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Aug 2025 | 20,000 | 216,569 | - | - | Option to Purchase Common Stock | |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Aug 2025 | 20,000 | 236,569 | - | - | Option to Purchase Common Stock | |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.11 per share. | 11 Aug 2025 | 20,000 | 753,719 (0%) | 0% | 8.1 | 162,200 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.11 per share. | 11 Aug 2025 | 20,000 | 753,719 (0%) | 0% | 8.1 | 162,200 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 63.01 per share. | 11 Aug 2025 | 18,717 | 735,002 (0%) | 0% | 63.0 | 1,179,321 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 64.14 per share. | 11 Aug 2025 | 14,948 | 738,771 (0%) | 0% | 64.1 | 958,839 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 63.24 per share. | 11 Aug 2025 | 13,042 | 740,677 (0%) | 0% | 63.2 | 824,802 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 64.00 per share. | 11 Aug 2025 | 6,958 | 733,719 (0%) | 0% | 64.0 | 445,319 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 64.83 per share. | 11 Aug 2025 | 5,052 | 733,719 (0%) | 0% | 64.8 | 327,511 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 63.60 per share. | 11 Aug 2025 | 1,283 | 733,719 (0%) | 0% | 63.6 | 81,596 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.11 per share. | 08 Jul 2025 | 20,000 | 753,719 (0%) | 0% | 8.1 | 162,200 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jul 2025 | 20,000 | 256,569 | - | - | Option to Purchase Common Stock | |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jul 2025 | 20,000 | 276,569 | - | - | Option to Purchase Common Stock | |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jul 2025 | 20,000 | 296,569 | - | - | Option to Purchase Common Stock | |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.11 per share. | 08 Jul 2025 | 20,000 | 753,719 (0%) | 0% | 8.1 | 162,200 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.11 per share. | 08 Jul 2025 | 20,000 | 753,719 (0%) | 0% | 8.1 | 162,200 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 56.43 per share. | 08 Jul 2025 | 19,792 | 733,927 (0%) | 0% | 56.4 | 1,116,783 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 55.74 per share. | 08 Jul 2025 | 16,402 | 733,719 (0%) | 0% | 55.7 | 914,215 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 57.62 per share. | 08 Jul 2025 | 15,746 | 733,719 (0%) | 0% | 57.6 | 907,237 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 56.74 per share. | 08 Jul 2025 | 4,254 | 749,465 (0%) | 0% | 56.7 | 241,380 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 54.48 per share. | 08 Jul 2025 | 3,598 | 750,121 (0%) | 0% | 54.5 | 196,030 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 57.08 per share. | 08 Jul 2025 | 208 | 733,719 (0%) | 0% | 57.1 | 11,872 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.11 per share. | 20 Jun 2025 | 20,000 | 753,719 (0%) | 0% | 8.1 | 162,200 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jun 2025 | 20,000 | 316,569 | - | - | Option to Purchase Common Stock | |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jun 2025 | 20,000 | 336,569 | - | - | Option to Purchase Common Stock | |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jun 2025 | 20,000 | 356,569 | - | - | Option to Purchase Common Stock | |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.11 per share. | 20 Jun 2025 | 20,000 | 753,719 (0%) | 0% | 8.1 | 162,200 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 52.57 per share. | 20 Jun 2025 | 20,000 | 733,719 (0%) | 0% | 52.6 | 1,051,460 | Common Stock |